Phadiatop
Allergy0 parametersReport in 48HrsAt Home
No Fasting Required
Details
Detects IgE antibodies against common inhalant allergens, helping identify atopy (the genetic tendency to develop allergic diseases)
₹1,610₹1,950
17% OFF
FREE:AI Insights
Phadiatop Test Information Guide
- Why is it done?
- Screening test to detect the presence of IgE antibodies against common environmental allergens
- Evaluates IgE sensitization to 10 common allergen groups: inhalant allergens (birch pollen, timothy grass, mugwort, house dust mites, cat dander, dog dander) and food allergens (milk, peanut, shrimp)
- Used when patients present with symptoms suggesting allergic disease such as rhinitis, asthma, eczema, or food allergies
- Serves as an initial screening tool before more specific allergen-specific IgE testing
- Typical timing: performed when allergic symptoms are present or when there is clinical suspicion of atopic disease
- May be used for epidemiological surveys to assess allergic sensitization in populations
- Normal Range
- Result: Negative (Class 0) - IgE <0.35 kU/L (kilo Units per Liter)
- Positive Results (indicate allergen sensitization):
- • Class 1: 0.35 - 0.69 kU/L
- • Class 2: 0.70 - 3.49 kU/L
- • Class 3: 3.50 - 17.49 kU/L
- • Class 4: 17.50 - 52.49 kU/L
- • Class 5: 52.50 - 100 kU/L
- • Class 6: >100 kU/L
- Interpretation: Negative result suggests no clinically relevant sensitization to the tested allergen panel; however, specific allergen sensitization cannot be ruled out for allergens not included in the panel
- Positive results indicate allergenic sensitization to one or more of the tested allergens; higher classes correlate with higher levels of allergen-specific IgE antibodies
- Unit of measurement: kU/L (kilo International Units per Liter)
- Interpretation
- Negative Result (Class 0, <0.35 kU/L): No detectable IgE antibodies to the common allergen panel; indicates low likelihood of IgE-mediated allergic sensitization to tested allergens; does not exclude allergies to allergens outside the panel or non-IgE mediated allergic reactions
- Class 1-2 (0.35-3.49 kU/L): Low level sensitization; clinical relevance depends on patient symptoms; may represent early sensitization or cross-reactivity
- Class 3-4 (3.50-52.49 kU/L): Moderate to high level sensitization; likely clinically relevant; should prompt specific allergen testing and clinical correlation
- Class 5-6 (>52.50 kU/L): Very high level sensitization; clinically highly relevant; indicates strong allergic sensitization requiring specific allergen identification and therapeutic intervention
- Factors affecting results:
- • Recent antihistamine use may suppress but not eliminate IgE response
- • Age - IgE sensitization patterns change over lifespan
- • Seasonal variation in IgE levels for seasonal allergens
- • Genetic predisposition and atopic status
- • Recent immunosuppressive therapy may reduce IgE levels
- Clinical significance: Positive results support allergic disease diagnosis when combined with clinical symptoms; however, IgE sensitization alone does not diagnose clinical allergy - clinical correlation is essential
- Associated Organs
- Primary organ systems: Immune system (B lymphocytes producing IgE), respiratory tract, gastrointestinal tract, skin, and mucous membranes
- Medical conditions associated with abnormal results:
- • Allergic rhinitis (hay fever) - environmental allergen sensitization
- • Allergic asthma - lower airway inflammation and bronchospasm
- • Atopic dermatitis (eczema) - IgE-mediated skin inflammation
- • Food allergy - oral allergy syndrome, gastrointestinal symptoms
- • Allergic conjunctivitis - ocular inflammation
- • Atopic syndrome - multiple allergic manifestations
- Diseases this test helps diagnose or monitor:
- • IgE-mediated allergic diseases
- • Atopic conditions (allergic triad)
- • Chronic rhinosinusitis with allergic component
- Potential complications or risks associated with abnormal results:
- • Anaphylaxis risk - severe allergic reactions to identified allergens
- • Chronic inflammation - persistent allergic inflammation may lead to tissue damage
- • Secondary infections - damaged respiratory epithelium susceptible to infections
- • Asthma exacerbations - untreated allergen exposure in asthmatic patients
- • Quality of life impairment - chronic symptoms affecting daily functioning
- Follow-up Tests
- Additional tests recommended based on positive results:
- • Allergen-specific IgE testing (ImmunoCAP, RAST) - to identify specific allergens causing sensitization from within the panel
- • Skin prick testing - confirmatory testing with better specificity; useful for clinical correlation
- • Intradermal testing - more sensitive for detecting lower-level sensitization when clinical suspicion high
- • Total IgE - to assess overall allergic load and atopic status
- • Component-resolved diagnostics (CRD) - identifies sensitization to specific allergenic proteins for precise allergen characterization
- Further investigations that might be needed:
- • Pulmonary function testing (spirometry) - if respiratory symptoms or asthma suspected
- • Methacholine challenge test - to evaluate airway hyperresponsiveness
- • Nasal endoscopy - for evaluation of allergic rhinitis complications
- • Oral food challenge - if food allergy suspected despite negative serum testing
- • Rhinolaryngoscopy - assessment of upper airway involvement
- Monitoring frequency for ongoing conditions:
- • Annual monitoring in patients with persistent allergic disease and high IgE levels
- • Monitoring before and during allergen immunotherapy (AIT) - to assess treatment efficacy
- • Re-testing if clinical symptoms persist despite negative initial results
- Related tests providing complementary information:
- • Tryptase level - marker of mast cell activation and baseline for anaphylaxis evaluation
- • Eosinophil count - supports allergic disease diagnosis; elevated in parasitic infections
- • IgE and IgG subclass measurements - additional immune response characterization
- • Allergen microarray - comprehensive analysis of sensitization patterns
- Fasting Required?
- Fasting Required: No
- Fasting duration: Not applicable - This is a blood test that does not require fasting
- Food and beverage: Patient may eat and drink normally before the test
- Medications to avoid:
- • Antihistamines (H1 and H2 blockers) - should ideally be discontinued 3-7 days before testing as they may suppress IgE-mediated mast cell reactions in skin testing correlation studies
- • Note: Blood test is not affected by antihistamines; this applies mainly to concurrent skin testing
- • Immunosuppressive therapy may reduce IgE levels but testing can still be performed
- Other patient preparation requirements:
- • Inform phlebotomist or healthcare provider of current medications before blood draw
- • Inform of any recent infections, vaccinations, or immunological events (may temporarily elevate IgE)
- • Blood sample collection via venipuncture - standard collection procedure
- • No special positioning or activity restrictions required before or after test
- • May resume normal activities immediately after blood draw
- • Optimal testing conditions: Perform during periods without acute infection or severe stress, which may temporarily alter immune responses
How our test process works!
